Corcept Therapeutics, Inc. (CORT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Apellis Pharmaceuticals, Inc.

Insmed, Inc.

ACADIA Pharmaceuticals, Inc.

Amicus Therapeutics, Inc.

Prestige Consumer Healthcare, Inc.

Organon & Co.

Perrigo Co. Plc

Corcept Therapeutics, Inc.

Cerevel Therapeutics Holdings, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Corcept Therapeutics, Inc. ?

With a fall in Net Sales of -18.42%, the company declared Very Negative results in Mar 26

The company has declared negative results for the last 3 consecutive quarters
OPERATING CASH FLOW(Y) Lowest at USD 120.1 MM
ROCE(HY) Lowest at 7.06%
NET SALES(Q) At USD 164.9 MM has Fallen at -13.37%

With ROE of 15.15%, it has a very expensive valuation with a 6.51 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 9.81%, its profits have fallen by -29.7%

Underperformed the market in the last 1 year

The stock has generated a return of 9.81% in the last 1 year, much lower than market (S&P 500) returns of 22.99%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Corcept Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Corcept Therapeutics, Inc.

9.81%

1.78

80.08%

S&P 500

22.99%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.56%

EBIT Growth (5y)

-18.96%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

1.03

Tax Ratio

1.56%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

80.18%

ROCE (avg)

111.37%

ROE (avg)

21.09%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.51

EV to EBIT

85.91

EV to EBITDA

82.43

EV to Capital Employed

13.91

EV to Sales

5.05

PEG Ratio

Dividend Yield

ROCE (Latest)

16.19%

ROE (Latest)

15.15%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.23% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 12.09 times

-26What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 120.1 MM

ROCE(HY)

Lowest at 7.06%

NET SALES(Q)

At USD 164.9 MM has Fallen at -13.37%

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.99 times

OPERATING PROFIT(Q)

Lowest at USD -49 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -29.72 %

PRE-TAX PROFIT(Q)

Lowest at USD -44.72 MM

NET PROFIT(Q)

Lowest at USD -31.2 MM

EPS(Q)

Lowest at USD -0.3

Here's what is working for Corcept Therapeutics, Inc.

Debtors Turnover Ratio

Highest at 12.09 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0.23% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Corcept Therapeutics, Inc.

Pre-Tax Profit

At USD -44.72 MM has Fallen at -369.11%

over average net sales of the previous four periods of USD 16.62 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -31.2 MM has Fallen at -227.14%

over average net sales of the previous four periods of USD 24.54 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 164.9 MM has Fallen at -13.37%

over average net sales of the previous four periods of USD 190.35 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD 120.1 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -49 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -29.72 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -44.72 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -31.2 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.3

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Lowest at 0.99 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio